Stryker, Gilead Sciences, and Humana are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of companies involved in healthcare, such as pharmaceutical and biotech firms, medical-device makers, and healthcare providers. Investors may buy them to gain exposure to the healthcare sector, but their performance can be affected by factors such as regulation, research results, and demand for medical services. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Stryker (SYK)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
NYSE SYK traded up $8.09 during mid-day trading on Tuesday, reaching $318.81. 1,521,762 shares of the company's stock traded hands, compared to its average volume of 2,515,933. Stryker has a 1-year low of $267.00 and a 1-year high of $389.33. The company has a fifty day simple moving average of $292.44 and a 200-day simple moving average of $322.36. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The company has a market cap of $121.37 billion, a price-to-earnings ratio of 33.90, a P/E/G ratio of 2.14 and a beta of 0.78.
Read Our Latest Research Report on SYK
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of GILD traded up $2.91 during trading on Tuesday, reaching $170.49. The company's stock had a trading volume of 2,299,541 shares, compared to its average volume of 6,769,018. The company has a fifty day moving average of $155.43 and a two-hundred day moving average of $141.94. Gilead Sciences has a twelve month low of $116.88 and a twelve month high of $176.58. The company has a market cap of $211.47 billion, a price-to-earnings ratio of -53.95 and a beta of 0.35. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84.
Read Our Latest Research Report on GILD
Humana (HUM)
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Shares of Humana stock traded down $18.56 on Tuesday, hitting $442.69. 634,600 shares of the company's stock traded hands, compared to its average volume of 1,646,771. Humana has a 52-week low of $163.11 and a 52-week high of $462.87. The company has a quick ratio of 1.74, a current ratio of 1.65 and a debt-to-equity ratio of 0.61. The stock has a market cap of $53.17 billion, a P/E ratio of 43.11, a PEG ratio of 2.11 and a beta of 0.65. The firm's 50-day moving average is $409.75 and its 200 day moving average is $318.25.
Read Our Latest Research Report on HUM
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.